VivoSim Labs Inc. (NASDAQ: VIVS) Takes Aim at Pharma’s 92% Drug-Failure Problem
https://thestreetreports.com/vivosim-labs-inc...e-problem/
Sept. 18, 2026 Approximately 92% of drugs entering clinical trials fail before receiving regulatory approval, leaving the pharmaceutical industry with a success rate of only about 8%. VivoSim Labs Inc. (NASDAQ: VIVS) is developing human-relevant laboratory models designed to identify potential failures earlier before drug developers commit substantial capital to human trials.
VivoSim’s technology uses engineered three-dimensional human tissues, commonly described as 3D biology, to provide a more realistic picture of how experimental medicines may behave inside the human body. Unlike flat cell cultures or animal testing alone, VivoSim’s models reproduce important structures and biological functions found in human organs.
The company’s NAMkind™ platform includes human liver and intestinal tissue models that can help researchers evaluate toxicity and other biological responses during preclinical development. By identifying weak or potentially dangerous compounds earlier, VivoSim could help pharmaceutical companies reduce late-stage failures, control development costs and concentrate resources on candidates with stronger prospects.
Alongside VivoSim Labs Inc. (NASDAQ: VIVS),investors are watching other potential multibagger stocks showing active trading, including Quanome Technologies, Inc. (NASDAQ: QNME), Murano Global (NASDAQ: MRNO), Generation Properties, Inc. (NASDAQ: GIPR), TruGolf Inc (NASDAQ: TRUG) and IGC Pharma Inc (NYSE: IGC) as momentum and trading activity put the group in focus.
The commercial potential of the technology is highlighted by its connection to Eli Lilly and Company (NYSE: LLY). Technology associated with VivoSim’s intestinal models contributed to identifying a Crohn’s disease drug candidate later acquired by Lilly. VivoSim received a $5 million milestone payment related to the divested FXR program and may be eligible for up to $45 million in additional milestone payments.
With the pharmaceutical industry seeking faster, safer and more predictive development methods, VivoSim is targeting one of medicine’s largest challenges: improving the odds that promising drug candidates ultimately reach patients.
https://thestreetreports.com/vivosim-labs-inc...e-problem/
Sept. 18, 2026 Approximately 92% of drugs entering clinical trials fail before receiving regulatory approval, leaving the pharmaceutical industry with a success rate of only about 8%. VivoSim Labs Inc. (NASDAQ: VIVS) is developing human-relevant laboratory models designed to identify potential failures earlier before drug developers commit substantial capital to human trials.
VivoSim’s technology uses engineered three-dimensional human tissues, commonly described as 3D biology, to provide a more realistic picture of how experimental medicines may behave inside the human body. Unlike flat cell cultures or animal testing alone, VivoSim’s models reproduce important structures and biological functions found in human organs.
The company’s NAMkind™ platform includes human liver and intestinal tissue models that can help researchers evaluate toxicity and other biological responses during preclinical development. By identifying weak or potentially dangerous compounds earlier, VivoSim could help pharmaceutical companies reduce late-stage failures, control development costs and concentrate resources on candidates with stronger prospects.
Alongside VivoSim Labs Inc. (NASDAQ: VIVS),investors are watching other potential multibagger stocks showing active trading, including Quanome Technologies, Inc. (NASDAQ: QNME), Murano Global (NASDAQ: MRNO), Generation Properties, Inc. (NASDAQ: GIPR), TruGolf Inc (NASDAQ: TRUG) and IGC Pharma Inc (NYSE: IGC) as momentum and trading activity put the group in focus.
The commercial potential of the technology is highlighted by its connection to Eli Lilly and Company (NYSE: LLY). Technology associated with VivoSim’s intestinal models contributed to identifying a Crohn’s disease drug candidate later acquired by Lilly. VivoSim received a $5 million milestone payment related to the divested FXR program and may be eligible for up to $45 million in additional milestone payments.
With the pharmaceutical industry seeking faster, safer and more predictive development methods, VivoSim is targeting one of medicine’s largest challenges: improving the odds that promising drug candidates ultimately reach patients.
